

Date 31 August 2026
Your Ref
Our Ref 11800

Enquiries to Richard Mutch
Extension 35687
Direct Line 0131 465 5687
loth.freedomofinformation@nhs.scot
richard.mutch@nhs.scot

Dear

FREEDOM OF INFORMATION – DERMATOLOGY PRESCRIBING

I write in response to your request for information in relation to dermatology prescribing.

Question:

1. How many patients were treated in the last 4 months (April to July 2026) by the dermatology department with each of the following products:

- Abrocitinib
- Acitretin
- Alitretinoin
- Azathioprine
- Baricitinib
- Ciclosporin
- Dupilumab
- Lebrikizumab
- Methotrexate
- Mycophenolate mofetil
- Pimecrolimus
- Phototherapy (UVB or PUVA) - for Atopic Dermatitis only
- Tacrolimus ointment
- Tralokinumab
- Upadacitinib
- Nemolizumab

Answer:

April 2026 - July 2026	
Medication	Patient Count
Abrocitinib	26
Acitretin	63
Alitretinoin	18
Azathioprine	6
Baricitinib	5<

Ciclosporin	69
Dupilumab	290
Lebrikizumab	54
Methotrexate	165
Mycophenolate Mofetil	7
Pimecrolimus	0
Phototherapy UVB or PUVA (Atopic Dermatitis Only)	Information Unavailable
Tacrolimus Ointment	Information Unavailable
Tralokinumab	11
Upadacitinib	44
Nemolizumab	21

Question:

2. In the last 4 months, how many new patients have been initiated* on the following treatments by the dermatology department

- Abrocitinib
- Baricitinib
- Dupilumab
- Lebrikizumab
- Tralokinumab
- Upadacitinib
- Nemolizumab

*Patients are considered initiated if they have not been treated in the previous 8 months with any of the drugs that are part of the named regimen

Answer:

For patients treated with specified medicines within NHS Lothian services from April 2026 - July 2026, below patient counts for those not treated in the previous eight months period (August 2025 - March 2026) with specified medications.	
Medication	Patient Count
Abrocitinib	5<
Baricitinib	0
Dupilumab	36
Lebrikizumab	13
Tralokinumab	0
Upadacitinib	5<
Nemolizumab	0

Question:

3. Of the patients treated in the last 4 months with any of the products listed in question 1, please provide the number of patients by the following age group:

- 6 months to 5
- Age 6-11
- Age 12-17
- Age 18 and above

Answer:

Medication	April 2026 - July 2026			
	0-5	6-11	12-17	18 and above
Abrocitinib	0	0	5<	25
Acitretin	0	0	0	63
Alitretinoin	0	0	0	18
Azathioprine	0	0	0	6
Baricitinib	0	0	0	5<
Ciclosporin	0	0	5<	67
Dupilumab	5<	8	8	273
Lebrikizumab	0	0	5<	53
Methotrexate	0	5<	12	150
Mycophenolate Mofetil	0	0	0	7
Pimecrolimus	0	0	0	0
Phototherapy UVB or PUVA (Atopic Dermatitis Only)	Information Unavailable	Information Unavailable	Information Unavailable	Information Unavailable
Tacrolimus Ointment	Information Unavailable	Information Unavailable	Information Unavailable	Information Unavailable
Tralokinumab	0	0	0	11
Upadacitinib	0	0	5<	43
Nemolizumab	0	0	5<	19

To protect the identity of the individuals involved any figure of 5 or less has not been shown in the table above. Since we do not have their consent to release this data from their records, the information is exempt under section 38(1)(b) of the Freedom of Information (Scotland) Act i.e. to provide it would breach the Data Protection Act (2018).

Question:

4. How many patients have received treatment by the dermatology department for Prurigo Nodularis in the last 4 months with each of the following products:
- Dupilumab
 - Nemolizumab

Answer:

No information. This is diagnosis specific and we do not collect this data.

I hope the information provided helps with your request.

If you are unhappy with our response to your request, you do have the right to request us to review it. Your request should be made within 40 working days of receipt of this letter, and we will reply within 20 working days of receipt. If our decision is unchanged following a review and you remain dissatisfied with this, you then have the right to make a formal complaint to the Scottish Information Commissioner within 6 months of receipt of our review response. You can do this by using the Scottish Information Commissioner's Office online appeals service at www.itspublicknowledge.info/Appeal. If you remain dissatisfied with the Commissioner's response you then have the option to appeal to the Court of Session on a point of law.

If you require a review of our decision to be carried out, please write to the FOI Reviewer at the email address at the head of this letter. The review will be undertaken by a Reviewer who was not involved in the original decision-making process.

FOI responses (subject to redaction of personal information) may appear on NHS Lothian's Freedom of Information website at: <https://org.nhslothian.scot/FOI/Pages/default.aspx>

Yours sincerely

ALISON MACDONALD
Executive Director, Nursing
Cc: Chief Executive